Drug
Rilzabrutinib
Rilzabrutinib: highest development phase Phase 3, developed by Sanofi. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| rilzabrutinib NCT07216079 | Phase 3 | Immune Thrombocytopenia |
| rilzabrutinib NCT07923305 | Phase 2/3 | Immunodeficiency Common Variable |
Latest
Follow Rilzabrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.